Breaking News Instant updates and real-time market news.

VIRT

Virtu Financial

$20.12

-0.28 (-1.37%)

, IVZ

Invesco

$23.01

0.13 (0.57%)

04:55
10/02/18
10/02
04:55
10/02/18
04:55

Securities Industry & Financial Markets Association to hold annual meeting

SIFMA Annual Meeting 2018 will be held in Washington, D.C. on October 1-2.

VIRT

Virtu Financial

$20.12

-0.28 (-1.37%)

IVZ

Invesco

$23.01

0.13 (0.57%)

IEX

IDEX Corp.

$151.05

0.48 (0.32%)

BR

Broadridge

$130.06

-1.94 (-1.47%)

C

Citi

$71.95

0.2 (0.28%)

JPM

JPMorgan

$113.55

0.71 (0.63%)

SCHW

Charles Schwab

$49.55

0.4 (0.81%)

BAC

Bank of America

$29.66

0.19 (0.64%)

MS

Morgan Stanley

$46.64

0.07 (0.15%)

BLK

BlackRock

$473.32

2.165 (0.46%)

ACN

Accenture

$173.53

3.35 (1.97%)

WFC

Wells Fargo

$52.26

-0.3 (-0.57%)

GS

Goldman Sachs

$225.58

1.25 (0.56%)

ALLY

Ally Financial

$26.35

-0.095 (-0.36%)

HBAN

Huntington Bancshares

$14.93

0.015 (0.10%)

FNMA

Fannie Mae

$0.00

(0.00%)

MET

MetLife

$46.77

0.05 (0.11%)

UBS

UBS

$15.57

-0.165 (-1.05%)

NTRS

Northern Trust

$103.67

1.55 (1.52%)

COWN

Cowen Group

$16.55

0.25 (1.53%)

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 04

    Oct

  • 12

    Oct

  • 13

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 19

    Oct

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 13

    Nov

  • 14

    Jan

  • 26

    Feb

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

VIRT Virtu Financial
$20.12

-0.28 (-1.37%)

09/19/18
09/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aerpio Pharmaceuticals (ARPO) initiated with a Buy at Guggenheim. 2. Vocera (VCRA) initiated with a Buy at Jefferies. 3. Veoneer (VNE) initiated with a Neutral at Buckingham. 4. Virtu Financial (VIRT) initiated with a Neutral at Compass Point. 5. Internap (INAP) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
MSCO
08/08/18
INITIATION
Target $22
MSCO
Equal Weight
Virtu Financial initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Michael Cyprys initiated Virtu Financial with an Equal Weight rating and $22 price target, citing near-term concerns over its dependence on market volatility and concentration in U.S. equities. Over the longer-term, Cyprys sees Virtu having a compelling longer-term growth story given its operating leverage potential and sophisticated market-making platform, he added.
08/08/18
08/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Optinose (OPTN) initiated with an Overweight at Cantor Fitzgerald. 2. BioCryst (BCRX) reinstated with an Overweight at JPMorgan. 3. Dillard's (DDS) initiated with an Outperform at Wedbush. 4. Virtu Financial (VIRT) initiated with an Equal Weight at Morgan Stanley. 5. Assembly Biosciences (ASMB) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/18
COMP
09/19/18
INITIATION
Target $23
COMP
Neutral
Virtu Financial initiated with a Neutral at Compass Point
Compass Point analyst Chris Allen initiated Virtu Financial with a Neutral and $23 price target saying the challenging operating environment in Q2 has carried over to Q3 and in most asset classes the environment has worsened.
IVZ Invesco
$23.01

0.13 (0.57%)

09/24/18
SBSH
09/24/18
NO CHANGE
SBSH
Neutral
Citi sees little benefit to Invesco from acquisition of OppenheimerFunds
Citi analyst William Katz's analysis shows little strategic or financial benefit to Invesco buying Massachusetts Mutual Life Insurance's OppenheimerFunds unit. His preliminary work suggests such a deal results in little earnings accretion and no economic value creation. As such, the analyst does not see such a transaction accelerating Invesco's ability to reach its aspirational goal of 3% to 5% long-term NNA growth. Katz keeps a Neutral rating on the shares.
09/24/18
JPMS
09/24/18
NO CHANGE
Target $29
JPMS
Overweight
Invesco investors won't like possible Oppenheimer deal, says JPMorgan
Following press reports that Invesco is in talks to acquire Oppenheimer Funds, JPMorgan analyst Kenneth Worthington says he does not expect investors will like the possible deal. Given negative industry trends, particularly for active management, the threat of further fee compression, outflows and increased demand for investment, investors would need more from an Invesco deal to get excited about the outlook for the stock, Worthington tells investors in a research note. The analyst, however, believes Oppenheimer is a good fit for Invesco in terms of business mix and capabilities and thinks the deal can be 10% accretive, similar to Van Kampen. He keeps an Overweight rating on Invesco with a $29 price target.
02/13/18
DBAB
02/13/18
UPGRADE
Target $38
DBAB
Buy
Invesco upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Brian Bedell upgraded Invesco to Buy while lowering his price target for the shares to $38 from $39. The analyst views the recent pullback in shares as a buying opportunity. Asset manager valuations are now "significantly depressed" relative to better fundamentals, Bedell tells investors in a research note.
07/13/18
KBWI
07/13/18
DOWNGRADE
KBWI
Market Perform
Invesco downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Robert Lee downgraded Invesco to Neutral and cut his price target to $29 from $36 telling investors he expects flow trends to remain challenging over the near term and sees few near-term catalysts for improvement despite a discounted valuation.
IEX IDEX Corp.
$151.05

0.48 (0.32%)

07/26/18
WELS
07/26/18
NO CHANGE
Target $170
WELS
Outperform
IDEX Corp. price target raised to $170 from $165 at Wells Fargo
Wells Fargo analyst Allison Poliniak-Cusic raised her price target for IDEX Corp. to $170 from $165 as Q2 core momentum drives another beat and raise. The analyst reiterates an Outperform rating on the shares.
02/01/18
RHCO
02/01/18
NO CHANGE
Target $145
RHCO
Hold
IDEX Corp price target raised to $145 from $129 at SunTrust
SunTrust analyst Charles Brady raised his price target on IDEX to $145 after the company's Q4 earnings beat. The analyst notes the company's strong organic growth and incoming orders as well as improved margins, adding he is "hard pressed" to find any areas of weakness. Brady says "valuation" is his only "sticking point", suggesting that further upside in the near term may be limited.
01/31/18
BMOC
01/31/18
NO CHANGE
Target $143
BMOC
Market Perform
IDEX Corp price target raised to $143 from $133 at BMO Capital
BMO Capital analyst Scott Graham raised his price target on IDEX to $143 and kept his Market Perform rating after the company's Q4 earnings beat. The analyst notes that the company has momentum in most businesses and M&A should accelerate this year, but believes the valuation is an "obstacle" to more meaningful upside.
04/12/18
DADA
04/12/18
INITIATION
Target $140
DADA
Neutral
IDEX Corp. initiated with a Neutral at DA Davidson
DA Davidson analyst Matt Summerville initiated IDEX Corp with a Neutral rating and a price target of $140. The analyst points to the company's exposure to positive demand trends in most of its key end markets, including industrial, life sciences, water/municipal, agriculture, and semiconductors, while also citing its "substantial free cash flow and strong balance sheet". Summerville warns however that IDEX's guidance is likely "biased upwards", while its multiple of 25.3-times his expected FY19 EPS is "fully valued". He recommends that investors add to positions if a "meaningful pullback" in the stock price materializes and views the company as a solid long-term holding.
BR Broadridge
$130.06

-1.94 (-1.47%)

08/29/18
08/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Outperform at Oppenheimer. 2. Systemax (SYX) initiated with a Market Perform at William Blair. 3. Broadridge (BR) initiated with a Buy at SunTrust. 4. Mercury General (MCY) initiated with an Outperform at Keefe Bruyette. 5. Immune Design (IMDZ) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/17/18
WOLF
07/17/18
INITIATION
Target $128
WOLF
Peer Perform
Broadridge initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Darrin Peller started Broadridge with a Peer Perform rating and $128 price target.Target $128.
08/29/18
RHCO
08/29/18
INITIATION
Target $150
RHCO
Buy
Broadridge initiated with a Buy at SunTrust
SunTrust analyst Oscar Turner initiated Broadridge with a Buy rating and a price target of $150, saying the company will continue to gain "meaningful customer wallet share" and generate long-term mid-single-digit organic revenue growth. Turner adds that the operating leverage of Broadridge suggests "at least" high-single-digit EPS expansion that should be consistent through its current cycle. The analyst believes that the company's "enduring" competitive advantages are derived from " regulatory-driven demand, scale, and few substitute solutions".
11/09/17
DADA
11/09/17
NO CHANGE
Target $86
DADA
Neutral
Broadridge price target raised to $86 from $80 at DA Davidson
DA Davidson analyst Peter Heckmann raised his price target on Broadridge to $86 and kept his Neutral rating following Q1 results. Heckmann estimates the company's organic revenue growth around 2%-3%, adding that while as much as 80% of its sales are "contractually recurring and fairly predictable", earnings variations are possible due to high-margin equity trade processing and event-driven proxy revenue streams.
C Citi
$71.95

0.2 (0.28%)

09/19/18
OPCO
09/19/18
NO CHANGE
OPCO
Outperform
U.S. banks 'in very good shape,' says Oppenheimer, favorites include BofA, Citi
Oppenheimer analyst Chris Kotowski tells investors in a research note that the U.S. banking group is on solid footing with balance sheets less risky than at any time over the last 33 years the firm covered the group and says his favorite bank stocks are Outperform-rated Bank of America (BAC), Citi (C), CIT (CIT) and Goldman Sachs (GS). However, Kotowski notes that banks are trading at an average relative P/E of just ~66% relative to the S&P 500 and returning to a historical avg valuation of 73%-80% range would imply over a thousand basis points of outperformance by the group. In his view, the U.S. banks are, on the whole, in "very good" shape.
09/25/18
WOLF
09/25/18
INITIATION
Target $91
WOLF
Outperform
Citi initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Citi with an Outperform and $91 price target.
08/28/18
WELS
08/28/18
NO CHANGE
Target $100
WELS
Outperform
Citi to benefit from potential U.S.-Mexico trade deal, says Wells Fargo
Wells Fargo analyst Mike Mayo believes Citi could gain more than other large U.S. banks from a U.S.-Mexico trade deal given its ownership of the second largest bank in Mexico, Citibanamex. In his view, Citi's stock had been hurt on perceptions of the U.S. relationship with Mexico. At a minimum, any new trade deal could reflect the absence of a negative and, on the upside, new potential growth opportunities, he contends. Mayo reiterates an Outperform rating and $100 price target on the shares.
07/27/18
RHCO
07/27/18
NO CHANGE
Target $240
RHCO
Buy
MasterCard price target raised to $240 from $215 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on MasterCard to $240 and kept his Buy rating, saying the company is demonstrating expansion of global market share while posting a 14% Q2 volume growth. The analyst adds that while MasterCard has a higher valuation than PayPal (PYPL) and Visa (V) - a 10% relative EBITDA premium - it is justified and may even be too narrow given its superior growth sustainability and margin upside.
JPM JPMorgan
$113.55

0.71 (0.63%)

08/22/18
SBSH
08/22/18
NO CHANGE
SBSH
JPMorgan mobile trading platform 'another salvo' on online brokers, says Citi
JPMorgan's (JPM) reported zero cost mobile trading service to be launched next week is "another salvo" in the war on broker dealers' fundamentals, Citi analyst William Katz tells investors in a research note. JPMorgan's move further underscores the commoditization risk to pricing across the retail broker dealer complex, particularly online brokers, the analyst adds. Further, he believes the new product adds an additional degree of difficulty to pricing a potential E-Trade (ETFC) acquisition or other retail broker deals. The analyst's work suggests negative 3% and negative 1% earnings risk to TD Ameritrade (AMTD) and Charles Schwab (SCHW), respectively. However, Katz believes much of the negativity is already priced into Ameritrade following yesterday's selloff. For Schwab, he believes continued pressure on Investor Services presents further downside risk in the stock from here.
08/22/18
DBAB
08/22/18
NO CHANGE
DBAB
JPMorgan mobile launch a catalyst for industry consolidation, says Deutsche
Deutsche Bank analyst Brian Bedell believes JPMorgan's (JPM) reported rollout of online trading to its 47M customers next week should be a catalyst for online broker industry consolidation. The analyst believes the news supports his TD Ameritrade (AMTD), E-Trade (ETFC) merger scenario thesis. He points out that his model already includes "substantial" trade price compression.
08/21/18
JEFF
08/21/18
NO CHANGE
JEFF
Jefferies says JPMorgan service could impact discount broker new account growth
Following news that JPMorgan (JPM) will soon be offering a digital brokerage service that offers 100 free trades, Jefferies analyst Daniel Fannon said he does not view this as much a threat to existing clients at TD Ameritrade (AMTD), E-Trade (ETFC) or Charles Schwab (SCHW), but he does think it may have an impact on new account growth over time. He thinks TD Ameritrade and E-Trade will take a "wait and see approach" and that Schwab is most likely to be looked to for a competitor response. Both TD Ameritrade and E-Trade are materially more dependent on trading as a percent of total revenue than Charles Schwab, added Fannon.
09/25/18
WOLF
09/25/18
INITIATION
Target $140
WOLF
Outperform
JPMorgan initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated JPMorgan with an Outperform and $140 price target.
SCHW Charles Schwab
$49.55

0.4 (0.81%)

09/19/18
09/19/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. WELLS FARGO UPGRADES TRANSOCEAN TO OUTPERFORM: Wells Fargo analyst Judson Bailey upgraded Transocean (RIG) to Outperform and raised his price target for the shares to $16 from $13. The analyst "significantly" increased his EBITDA and net asset value estimates across the offshore drilling space to reflect increasing demand combined with tightening availability for high spec ultra-deepwater rigs. This is quickly pushing dayrate expectations higher as well as the market value for ultra-deepwater assets, Bailey tells investors. The analyst cites Transocean's deepwater leverage for his upgrade to Outperform. In late morning trading, Transocean was higher by 3.6%. JEFFERIES UPGRADES E-TRADE TO BUY: Jefferies analyst Daniel Fannon upgraded E-Trade (ETFC) to Buy from Hold with an unchanged price target of $65. The stock's current valuation is attractive for the core business while the financial and strategic benefits as a takeout candidate remain intact, Fannon said. His favorite ideas in the group are E-Trade and Charles Schwab (SCHW). In late morning trading, E-Trade was higher by 3.5%. CREDIT SUISSE UPGRADES SUNPOWER: Credit Suisse analyst Michael Weinstein upgraded SunPower (SPWR) to Outperform from Neutral and raised his target price for shares to $10 from $8. Weinstein said the news that its interdigitated back contact solar modules manufactured in Malaysia will be exempted from U.S. import tariffs won't impact 2018 earnings, as the decision doesn't explicitly call out retroactiveness, but sees a benefit to 2019 and 2020 gross profit of $35M-$40M per year vs. prior estimates. In late morning trading, SunPower was higher by 4.7%. MORGAN STANLEY SAYS OIL SERVICES INDUSTRY ATTRACTIVE: Morgan Stanley analyst Connor Lynagh upgraded the oil services, drilling and equipment industry view to attractive, and initiated 14 stocks in the sector, including top Overweight picks Baker Hughes (BHGE), Halliburton (HAL), and Transocean. GUGGENHEIM RAISES NETFLIX PRICE TARGET: Guggenheim analyst Michael Morris raised his price target for Netflix (NFLX) to $420 from $360 and kept a Buy rating on the shares. The analyst believes that Netflix "subscriber penetration will significantly exceed what is implied in the company's current valuation." He thinks the company's Q3 launch of original local-market content in India and upgrades to its user experience will support further upside in the shares.
09/18/18
MSCO
09/18/18
NO CHANGE
Target $70
MSCO
Overweight
TD Ameritrade most logical buyer if E-Trade opts for sale, says Morgan Stanley
Morgan Stanley analyst Michael Cyprys noted that E-Trade (ETFC) in mid-2016 gave itself an 18- to 24-month deadline to improve core metrics or consider strategic options and that self-imposed strategic review deadline is nearing. The company plans to give an update on its review on the Q3 earnings call, likely in mid-October, he said. Of the potential acquirers identified in the media, Cyprys believes TD Ameritrade (AMTD) could possibly achieve the greatest accretion and therefore pay the most, making it the most logical buyer if E-Trade's board opts to pursue a sale. Charles Schwab (SCHW) is another potential acquirer, though he thinks such a combination could make less strategic sense. Goldman Sachs (GS) has said it is looking to build out its consumer business through mass market, but Cyprys concludes it is not the best bidder given regulatory hurdles, low synergies and low expected EPS accretion, he tells investors. The analyst keeps an Overweight rating and $70 price target on E-Trade shares.
09/25/18
WOLF
09/25/18
INITIATION
Target $54
WOLF
Underperform
Charles Schwab initiated with an Underperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Charles Schwab with an Underperform and $54 price target.
09/19/18
JEFF
09/19/18
UPGRADE
Target $65
JEFF
Buy
Jefferies upgrades E-Trade to Buy on valuation, possible takeout upside
Jefferies analyst Daniel Fannon upgraded E-Trade (ETFC) to Buy from Hold with an unchanged price target of $65. The stock's current valuation is attractive for the core business while the financial and strategic benefits as a takeout candidate remain intact, Fannon tells investors in a research note. In a takeout scenario, Fannon thinks E-Trade could be worth as much as low $70s per share. He views TD Ameritrade (AMTD) and Charles Schwab as the most likely buyers given the expense overlaps. The analyst believes increasing competition across the Discount Brokers industry will continue to favor the firms with greater scale and revenue diversity. His favorite ideas in the group are E-Trade and Charles Schwab.
BAC Bank of America
$29.66

0.19 (0.64%)

09/25/18
WOLF
09/25/18
INITIATION
Target $40
WOLF
Outperform
Bank of America initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Bank of America with an Outperform and $40 price target.
07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
07/17/18
BARD
07/17/18
NO CHANGE
Target $30
BARD
Neutral
Baird would be buyers of Bank of America on weakness
Baird analyst David George said he would remain a buyer of Bank of America shares on any weakness, stating that its operating leverage was impressive in Q2 and should continue along with solid execution. George maintained his Neutral rating and $30 price target on Bank of America shares.
MS Morgan Stanley
$46.64

0.07 (0.15%)

07/19/18
ARGS
07/19/18
NO CHANGE
Target $62
ARGS
Buy
Morgan Stanley saw strong Q2, recent price weakness 'unwarranted', says Argus
Argus analyst Stephen Biggar kept his Buy rating and $62 price target on Morgan Stanley after its Q2 earnings beat, saying the results were bolstered by strength across investment banking, trading, and asset management. The analyst also notes the pretax margin in the Morgan Stanley the wealth management segment was 27%, which is on the high end of the recently raised guidance, while its ROE of 14.9% was above the 10%-13% forecast range for 2018-19. Biggar further contends that the share price weakness in Morgan Stanley since mid-May is unwarranted by its fundamentals and believes investors are offered an "attractive entry point" for the stock.
07/19/18
07/19/18
UPGRADE

Market Perform
Morgan Stanley upgraded to Market Perform on more balanced risk/reward at Bernstein
As previously reported, Bernstein analyst Christian Bolu upgraded Morgan Stanley to Market Perform from Underperform saying that while he still sees some risks, his concerns are now better reflected in the stock given price underperformance over recent months. Wealth management still a risk, but now a better understood risk, he contends.
09/20/18
RBCM
09/20/18
NO CHANGE
Target $60
RBCM
Outperform
Morgan Stanley EPS ests lowered at RBC Capital on declining advisory fees
RBC Capital analyst Gerard Cassidy kept his Outperform rating and $60 price target on Morgan Stanley but lowered his FY18 EPS view to $4.70 from $4.88 and FY19 view to $5.15 from $5.47. The analyst says his new targets assume advisory fees declining 2% and Equity and Debt Capital Market segments fees decline of 0.9% and 2.3% respectively, even though he sees equity trading revenues rising 5.8%. Cassidy further expects Morgan Stanley's investment management revenue to fall "modestly" on anticipated funds outflow from "money market mutual fund sweeps".
09/25/18
WOLF
09/25/18
INITIATION
Target $61
WOLF
Outperform
Morgan Stanley initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Morgan Stanley with an Outperform and $61 price target.
BLK BlackRock
$473.32

2.165 (0.46%)

07/17/18
GSCO
07/17/18
NO CHANGE
Target $570
GSCO
Buy
BlackRock price target lowered to $570 from $605 at Goldman Sachs
Goldman Sachs analyst Alexander Blostein lowered his price target on BlackRock to $570 after its Q2 results, which highlighted a "challenging market backdrop" along with a deceleration in the company's organic fee growth to 4% from 7%. The analyst keeps his Buy rating on BlackRock however, stating that the slowdown in fees was likely "market driven" and does not reflect "company specific weaknesses", adding that BlackRock still has the "operating flexibility to deliver above trend operating income growth, while accelerating technology revenue growth". Blostein lowers his FY18 EPS forecast to $27.57 from $27.96 and FY19 to $30.81 from $31.64 to reflect lowers asset under management levels and lower ETF fee rates partially offset by stronger technology revenues and more accretion from stock buybacks.
07/02/18
JPMS
07/02/18
NO CHANGE
Target $547
JPMS
Overweight
BlackRock removed from Analyst Focus List at JPMorgan
JPMorgan analyst Kenneth Worthington removed BlackRock from his firm's Analyst Focus List and lowered his price target for the shares to $547 from $618. The analyst sees the macro environment as "less constructive" for BlackRock near term. Divergent beta trends have turned negative in recent months with both non-U.S. currencies and non-U.S. markets underperforming, Worthington tells investors in a research note. The analyst, however, continues to believe longer term secular trends are strong for iShares and keeps an Overweight rating on BlackRock.
07/13/18
07/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. VF Corp. (VFC) upgraded two notches to Buy from Underperform at BofA/Merrill with analyst Robert Ohmes saying he believes Vans momentum is sustainable and will be a "go-to-brand" for the back-to-school selling season. 2. United Rentals (URI) and Herc Holdings (HRI) were upgraded to Buy from Neutral at Buckingham. 3. Raymond James (RJF) upgraded to Buy from Neutral at Citi with analyst William Katz saying he still prefers alternative managers. 4. M.D.C. Holdings (MDC) upgraded to Neutral from Underweight at JPMorgan with analyst Michael Rehaut saying the current valuation appropriately reflects his outlook for above average order growth and margin expansion in 2018. 5. BlackRock (BLK) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Robert Lee saying shares deserve a premium valuation given its strong secular position and views the recent sell-off as a buying opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/18
KBWI
07/13/18
UPGRADE
KBWI
Outperform
BlackRock upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Robert Lee upgraded BlackRock to Outperform saying shares deserve a premium valuation given its strong secular position and views the recent sell-off as a buying opportunity. The analyst believes BlackRock will be able to sustain an organic growth rate over time in the mid-single-digit range, driving a premium valuation versus peers. Lee trimmed his price target on BlackRock to $590 from $617.
ACN Accenture
$173.53

3.35 (1.97%)

09/28/18
BMOC
09/28/18
NO CHANGE
Target $180
BMOC
Market Perform
Accenture price target raised to $180 from $170 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Accenture to $180, citing its latest earnings beat and "reasonable, if not conservative" FY19 guidance in spite of the expectations of a "deteriorating" macro environment. The analyst also notes that he expects continued gross margin expansion from Accenture, calling it a "best-in-class IT services provider", but keeps his Market Perform rating on the stock based on his high attrition cost concerns and "full" valuation.
09/28/18
FBCO
09/28/18
NO CHANGE
Target $170
FBCO
Neutral
Accenture price target raised to $170 from $160 at Credit Suisse
Credit Suisse analyst Charles Brennan maintained a Neutral rating on Accenture and raised his price target to $170 from $160 following the company's "solid" Q4 report. In a research note to investors, Brennan notes that while current momentum is strong, the announced FY19 revenue guidance is for 5%-8% growth, and while investors will assume the company will hit the high end of this range, "it is hard to see" how the shares can materially re-rate on this basis with management allowing for some macro risks.
09/28/18
ARGS
09/28/18
NO CHANGE
Target $200
ARGS
Buy
Accenture price target raised to $200 from $175 at Argus
Argus analyst Jim Kelleher raised his price target on Accenture to $200 and kept his Buy rating after its Q4 results, saying that while the company guided Q1 cautiously, it is typically "very conservative" in its outlook and tends to bump up its annual guidance at every quarter. The analyst is positive on the customers' engagement of Accenture services to assist them in digital transformation, stating that its "The New" business category which includes digital / cloud / security saw a "strong" double digit" annual growth. Kelleher adds that the company's premium valuation relative to its peer group is warranted by its "rising revenue and new orders, strong cash-growth trends, market-share gains, and increasing profitability".
10/01/18
RHCO
10/01/18
NO CHANGE
Target $178
RHCO
Hold
Accenture price target raised to $178 from $168 at SunTrust
SunTrust analyst Frank Atkins raised his price target on Accenture to $178, citing the "continued solid traction" in the company's digital segment while also reflecting the adjustments made for accounting and tax changes. Although the analyst believes that the company "deserves a premium" to its peer group thanks to its "strong rotation to digital" and "superior diversification", he sees near-term consensus estimates as fair. Atkins keeps his Hold rating on Accenture.
WFC Wells Fargo
$52.26

-0.3 (-0.57%)

09/28/18
UBSW
09/28/18
NO CHANGE
Target $63
UBSW
Buy
Wells Fargo app download data suggests no momentum slowdown, says UBS
UBS analyst Saul Martinez reassessed Wells Fargo client engagement and employee sentiment and found that app download data was encouraging and showed no slowdown in momentum. Employee sentiment, however, showed a material weakening. The analyst said meaningful improvements in earnings power and profitability require revenue to stabilize and the recent share weakness may be due to concerns that business momentum and top line growth will continue to lag. Martinez maintained his Buy rating and $63 price target on Wells Fargo shares.
09/25/18
WOLF
09/25/18
INITIATION
Target $71
WOLF
Outperform
Wells Fargo initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Wells Fargo with an Outperform and $71 price target.
09/17/18
EDJN
09/17/18
UPGRADE
EDJN
Buy
Wells Fargo upgraded to Buy from Hold at Edward Jones (Friday)
09/12/18
JPMS
09/12/18
NO CHANGE
JPMS
Underweight
Reported OCC rejection would be negative for Wells, says JPMorgan
According to Reuters, Office of the Comptroller of the Currency regulators have rejected Wells Fargo's plan to repay its auto customers who were pushed to buy unnecessary auto insurance, JPMorgan analyst Vivek Juneja tells investors in a research note. This rejection would be a negative for Wells as it may be required to spend more and take more time to satisfy regulators, the analyst writes. He also views the news negatively overall for the bank's ongoing regulatory issues. Juneja reiterates an Underweight rating on shares of Wells Fargo.
GS Goldman Sachs
$225.58

1.25 (0.56%)

08/15/18
VERT
08/15/18
NO CHANGE
VERT
Sell
Goldman involvement with Tesla 'doesn't mean anything,' says Vertical Research
Vertical Research analyst Gordon Johnson said Goldman Sachs (GS) being confirmed as a financial advisor to Tesla's (TSLA) proposed go-private offer "does not mean anything" beyond the "superficial optics" of the carmaker being able to "use Goldman's prestigious name to lend credence to the deal." Goldman is "in it for M&A fees" and agreeing to be an advisor is "not based on any inherent understanding of Tesla's value proposition, nor is it based on Goldman's confidence in Tesla's legal situation with respect to its significant issues surrounding disclosures and SEC involvement," according to Johnson, who maintains a Sell rating on Tesla shares.
09/25/18
WOLF
09/25/18
INITIATION
Target $290
WOLF
Outperform
Goldman Sachs initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Goldman Sachs with an Outperform and $290 price target.
ALLY Ally Financial
$26.35

-0.095 (-0.36%)

06/19/18
06/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ollie's Bargain Outlet (OLLI) initiated with a Hold at Loop Capital. 2. B&G Foods (BGS) assumed with a Neutral at Piper Jaffray. 3. Iterum Therapeutics (ITRM) initiated with an Outperform at RBC Capital and Leerink while being initiated with a Buy at Needham and Guggenheim. 4. Ingersoll-Rand (IR) initiated with an Outperform at Cowen. 5. Ally Financial (ALLY) initiated with a Neutral at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/18
BOFA
07/30/18
UPGRADE
Target $35
BOFA
Buy
Ally Financial upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Kenneth Bruce upgraded Ally Financial to Buy from Neutral and raised its price target to $36 from $33. Bruce said Ally continues to execute and sees earnings upside from strong business momentum and earnings growth and end is less concerned about cyclical pressures given favorable trends in auto sales, credit and used vehicle pricing.
06/29/18
JANY
06/29/18
UPGRADE
JANY
Buy
Ally Financial upgraded to Buy from Neutral at Janney Montgomery Scott
06/29/18
06/29/18
UPGRADE

Buy
Janney upgrades Ally Financial, Santander Consumer to Buy on CCAR results
As previously reported, Janney Montgomery Scott analyst John Rowan upgraded both Santander Consumer (SC) and Ally Financial (ALLY), each to Buy from Neutral, after the Federal Reserve released the results of its Comprehensive Capital Analysis and Review, or CCAR, tests and did not object to the capital plans for either. The capital actions approved for Santander Consumer do not alleviate its excess capital, but they are "significant," Rowan tells investor. Meanwhile, Ally's share repurchase plan is 32% higher than last year, noted Rowan, who raised his EPS estimates for both companies. He has a $36 fair value estimate on Ally shares and a $24 fair value estimate for Santander Consumer.
HBAN Huntington Bancshares
$14.93

0.015 (0.10%)

03/22/18
UBSW
03/22/18
INITIATION
Target $20
UBSW
Buy
Huntington Bancshares initiated with a Buy at UBS
UBS analyst Brock Vandervliet started Huntington Bancshares with a Buy rating and $20 price target. The analyst rolled out coverage last night on the Mid-Cap Banks. He sees performance differentiation "playing out more starkly" than investors may expect with "increasingly advantaged and disadvantaged participants."
06/29/18
06/29/18
NO CHANGE

Goldman says Wells Fargo, Huntington, Regions among biggest winners of CCAR
Goldman Sachs analyst Richard Ramsden said the Fed's CCAR results came in largely better than expected, calling Wells Fargo (WFC), Huntington Bancshares (HBAN), Regions Financial (RF), SunTrust (STI) and Fifth Third (FITB) the biggest relative winners in his view. He believes the market will be focused on banks' 25% dividend growth announcements and believes the CCAR results can be a catalyst for a relief rally.
06/29/18
DBAB
06/29/18
NO CHANGE
DBAB
Deutsche declares Wells Fargo, SunTrust, Huntington the CCAR winners
Deutsche Bank analyst Matt O'Connor views Wells Fargo (WFC), SunTrust (STI) and Huntington Bancshares (HBAN) as the winners of the Federal Reserve's Comprehensive Capital Analysis and Review. The banks separately disclosed planned dividend increases and buybacks for the next four quarters, O'Connor tells investors in a research note. He points out that while JPMorgan (JPM), KeyCorp (KEY) and M&T Bank (MTB) "all used the mulligan," he does not view this as negative.
06/29/18
WEDB
06/29/18
NO CHANGE
WEDB
Outperform
CCAR results 'very positive' for regional banks, says Wedbush
Wedbush analyst Peter Winter says the results of the CCAR for 2018 were "very positive" for the regional banks, as the average total capital return increased from 88% in the 2017 CCAR to 119%, above his forecast of 103%. In a research note to investors, Winter says the "winners" relative to his forecast were Regions Financial (RF), Huntington Bancshares (HBAN), Fifth Third (FITB), SunTrust (STI) and KeyCorp (KEY).
FNMA Fannie Mae
$0.00

(0.00%)

12/22/17
KBWI
12/22/17
NO CHANGE
KBWI
Keefe Bruyette keeps $1 price targets on Fannie and Freddie
The Federal Housing Finance Agency, as conservator of Fannie Mae (FNMA) and Freddie Mac (FMCC), and the Department of the Treasury agreed to reinstate a $3B capital reserve amount under the Senior Preferred Stock Purchase Agreements for each of the companies beginning in Q4, Keefe Bruyette analyst Bose George told investors last night in a research note. The government-sponsored enterprises are still expected to incur deferred tax asset write-downs if the corporate tax rate falls to 21% from the current 35%, George points out. He estimates that the write-down will be $12B for Fannie Mae and $7B for Freddie Mac. The analyst does not see the reinstatement of the capital buffer as a change in policy towards the GSEs. As such, George makes no changes to his outlook on the shares and keeps Underperform ratings on both Fannie and Freddie with $1 price targets. Fannie is down 2% to $2.78 while Freddie is down 3% to $2.60 in morning trading.
MET MetLife
$46.77

0.05 (0.11%)

03/26/18
03/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) and Analog Devices (ADI) upgraded to Outperform from Market Perform at Raymond James. 2. D.R. Horton (DHI) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying he sees the company as well positioned to absorb volume demand while maintaining gross margins. 3. RBS (RBS) upgraded to Buy from Hold at Deutsche Bank with the firm saying the recent underperformance of shares has brought an attractive entry point. 4. MetLife (MET) upgraded to Overweight from Neutral at Atlantic Equities. 5. Dollar Tree (DLTR) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying he believes the company is making "sensible investments" with Family Dollar to drive comp growth improvement into 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
FBCO
04/25/18
INITIATION
Target $67
FBCO
Outperform
MetLife initiated with an Outperform at Credit Suisse
Credit Suisse analyst Andrew Kligerman started MetLife with an Outperform rating and $67 price target as he believes its low valuation appears not to reflect the less equity-sensitive nature of its strong remaining businesses and likely a 12% ROE by 2020, supported by organic growth, capital management, and sizable cost savings.
06/04/18
GSCO
06/04/18
DOWNGRADE
Target $52
GSCO
Neutral
MetLife downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Alex Scott downgraded MetLife to Neutral and lowered his price target for the shares to $52 from $54. The analyst see slower progress towards return on equity improvement and believes some of the upside from capital return acceleration is behind the company at this point.
06/04/18
06/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Big Lots (BIG) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba saying the company got off to a "tough start in fiscal 2018 with a store sales decline and continued slowdown in furniture sales." 2. Jounce Therapeutics (JNCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he views the company's ASCO data as disappointing. 3. MetLife (MET) downgraded to Neutral from Buy at Goldman Sachs with analyst Alex Scott saying he see slower progress towards return on equity improvement and believes some of the upside from capital return acceleration is behind the company at this point. 4. Dollar Tree (DLTR) downgraded to Accumulate from Buy at Gordon Haskett. 5. SM Energy (SM) downgraded to Neutral from Outperform at Credit Suisse with analyst Betty Jiang saying she believes SM Energy's discount valuation is appropriate given it has greater than average downside risk in a constrained Permian takeaway environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
UBS UBS
$15.57

-0.165 (-1.05%)

02/14/18
02/14/18
DOWNGRADE
Target $48

Hold
Luxoft downgraded to Hold on 'elongated turnaround' at Pivotal Research
As previously reported, Pivotal Research analyst Lou Miscioscia downgraded Luxoft (LXFT) to Hold from Buy, as he now expects most of FY19 to be "a struggle." He had expected the company's two biggest customers - namely Deutsche Bank (DB) and UBS (UBS) - to be about flat for FY19, but now they are suggested to be down 20% and 5%, respectively, Miscioscia said. Noting also that the company cut its FY18 guidance along with its Q3 report, the analyst lowered his price target on Luxoft to $48 from $70.
05/22/18
JPMS
05/22/18
NO CHANGE
JPMS
Overweight
UBS added to European Analyst Focus List at JPMorgan
JPMorgan analyst Kian Abouhossein added UBS to his firm's European Analyst Focus List saying the company's newly merged wealth management business is the best-positioned globally relative to peers. The analyst calls UBS his top pick in wealth management.
07/25/18
SOCG
07/25/18
UPGRADE
SOCG
Buy
UBS upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Andrew Lim upgraded UBS to Buy and raised estimates to reflect modestly higher revenues and increasing momentum on buybacks.
01/18/18
FBCO
01/18/18
UPGRADE
FBCO
Outperform
Credit Suisse upgrades UBS after ultra high net worth market analysis
Credit Suisse analyst Jon Peace upgraded UBS to Outperform from Neutral and raised his price target for the shares to 22 francs from 17.50 francs. An analysis of global growth trends in the ultra high net worth market implies net new money growth could be near double current consensus, Peace tells investors in a research note. The analyst believes the end of tax regularization outflows in Q2 will see UBS Wealth deliver net new money at the top end of its 3%-5% guidance. Further, he believes the market is pricing in too low a probability of a buyback.
NTRS Northern Trust
$103.67

1.55 (1.52%)

09/25/18
WOLF
09/25/18
INITIATION
Target $118
WOLF
Peer Perform
Northern Trust initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Northern Trust with a Peer Perform and $118 price target.
04/02/18
04/02/18
UPGRADE
Target $121

Buy
Northern Trust upgraded to Buy on expense upside at Goldman Sachs
As previously reported, Goldman upgraded Northern Trust to Buy from Neutral with a $121 price target. Analyst Alexander Biostein thinks Street costs expectations have "right-sized" after disappointing expense trends while Northern's organic growth remains best in class. Biostein expects further share upside as cost cutting takes hold and sees capital optimization opportunities.
04/02/18
GSCO
04/02/18
UPGRADE
GSCO
Buy
Northern Trust upgraded to Buy from Neutral at Goldman Sachs
09/13/18
KBWI
09/13/18
NO CHANGE
Target $118
KBWI
Market Perform
Northern Trust deposits down about $2.5B quarter to date, says Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl noted that Northern Trust management said while presenting at a conference that so far total deposits have declined roughly $2.5B this quarter. Kleinhanzl has a Market Perform rating and $118 price target on Northern Trust shares, which are down $1.72, or 1.65%, to $103.06 heading into the close.
COWN Cowen Group
$16.55

0.25 (1.53%)

05/18/18
SDLR
05/18/18
INITIATION
Target $19
SDLR
Buy
Cowen Group resumed with a Buy at Sandler O'Neill
Sandler O'Neill analyst Sumeet Mody resumed coverage of Cowen Group with a Buy rating and $19 price target. Cowen offers a good fundamental story at an attractive valuation, Mody tells investors in a research note.
02/16/18
NOMU
02/16/18
UPGRADE
Target $16
NOMU
Buy
Cowen Group upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst Steven Chubak upgraded Cowen Group to Buy and raised his price target for the shares to $16 from $13. The analyst views the current valuation as compelling and is optimistic on the new CEO addressing the company's legacy issues.

TODAY'S FREE FLY STORIES

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.